LIVE WEBINAR
Share:

Aseptic Processing and Contamination Control Under EU GMP Annex 1: Practical Applications for Modern Sterile Operations

  • Date
    03 August 2026
  • 11.00 AM Eastern Time (US/Canada)
    03.00 PM GMT

Course is now LIVE. Click below to join the session.

This course helps sterile operations teams apply Annex 1 contamination control expectations to practical decisions involving monitoring data, interventions, investigations, escalation, and sterility assurance. 

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
REGISTRATION OPTIONS

Live session Plus
Complimentary 30 Days Streaming access

$290  |  One participant (viewer)

$390  |  Team (2 - 5 participants)

$490 |  Team (6 - 10 participants)

REGISTER FOR THE COURSE

US $290 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $290 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    Meredith Crabtree
  • Duration
    90 Minutes
  • Course ID
    TF1613
  • Live Q&A +
    Post-live Continued Learning
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

 

Why take this course?

Aseptic processing remains under close regulatory scrutiny as EU GMP Annex 1 places stronger emphasis on contamination control, sterility assurance, intervention management, environmental monitoring, and the effectiveness of Contamination Control Strategies. Many organizations have updated procedures, yet practical challenges remain when teams must translate Annex 1 expectations into daily operational decisions. These challenges often involve how contamination risks are evaluated, how routine interventions are interpreted, and how monitoring signals are acted upon. 


This webinar examines contamination control within modern sterile manufacturing operations through practical decision-making. Participants will evaluate how environmental monitoring trends, excursions, human interventions, contamination events, investigations, corrective actions, and CCS evidence support sterility assurance. The session focuses on recognizing early risk signals, justifying actions when information is incomplete, and maintaining sustainable aseptic operations aligned with Annex 1 expectations. 

Interpret Contamination Signals Earlier 

Participants will learn how environmental monitoring trends, excursions, and operational signals may indicate risk before a contamination event becomes clear. This supports better judgment when results appear inconclusive, interventions seem routine, or minor deviations require decisions under Annex 1 expectations. 

Apply CCS Thinking to Daily Operations 

Annex 1 expects contamination control to function as an active strategy, not isolated procedures. This session helps teams connect CCS principles to aseptic interventions, investigations, corrective actions, escalation decisions, and evidence supporting sterility assurance in real manufacturing conditions. 

Key Areas Covered

  • Sterility Assurance Expectations Under EU GMP Annex 1 
  • Environmental Monitoring Trends, Excursions, and Early Risk Signals 
  • Human Interventions and Their Impact on Critical Aseptic Operations 
  • Applying CCS Principles to Real Manufacturing and Operational Decisions 
  • Contamination Events, Investigations, and Escalation Decisions 
  • Corrective Actions That Address Root Causes Rather Than Immediate Symptoms 
  • Environmental Monitoring, CCS, and the Evidence Supporting Sterility Assurance 
  • Regulatory Expectations for Risk-Based Contamination Control Under Annex 1 

Who Must Attend

  • Quality Assurance (QA)
  • Sterile Manufacturing and Operations
  • Microbiology and Environmental Monitoring Personnel
  • Validation and Qualification Professionals
  • Quality Control (QC)
  • Manufacturing Science and Technical Services
  • Compliance and Quality Systems Professionals
  • Regulatory Affairs and Sterile Product Leadership
Meredith Crabtree
COURSE DIRECTOR

Meredith Crabtree

Meredith Crabtree has over 30 years of experience across regulated industries including laboratory, pharmaceutical, medical device, tissue, manufacturing, packaging, labeling, and distribution operations. Her work in regulatory assessments, third-party inspections, consent decree support, recall support, and quality training aligns directly with contamination control, inspection readiness, and quality decision-making in sterile operations. 

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How much evidence is needed before an environmental monitoring trend should trigger investigation or escalation? 

Waiting for definitive proof is rarely a defensible approach in sterile manufacturing. Environmental monitoring is intended to provide early warning, and its value declines if action is postponed until contamination becomes obvious or product impact is confirmed. 


Inspection discussions often focus on why an organization chose not to investigate an emerging pattern rather than why an investigation was initiated. A series of low-level recoveries, subtle shifts in microbial flora, repeated alert-level events, or gradual deterioration in a specific location may collectively warrant action even if individual results remain explainable. 


Documentation becomes difficult to defend when records evaluate each event independently without considering cumulative evidence. Reviewers generally expect trend evaluations to demonstrate how information was integrated over time rather than reviewed as isolated data points. 


Strong decisions are supported by documented rationale explaining why the observed pattern either justified escalation or remained consistent with the established contamination control strategy. 

What makes contamination investigations repeatedly identify different immediate causes while the same operational problems continue to occur? 

An operational failure point often develops when investigations stop at the first observable event instead of examining why similar conditions continue arising. A contaminated glove, an improper intervention, an equipment adjustment, or a cleaning deviation may explain the immediate incident without explaining why comparable events recur. 


Inspection observations frequently show investigations assigning different causes to successive contamination events while overlooking common factors such as workflow design, equipment accessibility, staffing practices, maintenance planning, or operational scheduling. 


Corrective actions directed only at individual events often provide temporary improvement before similar problems reappear under different circumstances. 


Evidence supporting a stronger investigation includes evaluation of recurring operational conditions, historical contamination patterns, process interactions, and management decisions influencing aseptic performance. Those broader assessments are generally more effective at preventing recurrence than repeatedly addressing isolated events. 

How should organizations defend aseptic manufacturing decisions when available evidence remains incomplete or inconclusive? 

A direct answer is that uncertainty should be documented and managed rather than concealed. Sterile manufacturing decisions frequently require action before every question can be answered, particularly when evaluating potential contamination events or atypical environmental monitoring results. 


Inspection friction often develops when records present highly confident conclusions despite limited supporting evidence. Reviewers generally recognize that uncertainty exists. Their attention turns toward how that uncertainty influenced decision-making. 


Documentation becomes substantially stronger when investigators explain what information was available, what information remained unavailable, what assumptions were made, how risk was evaluated, and why the selected action was considered appropriate despite incomplete evidence. 


Well-supported decisions demonstrate structured reasoning rather than absolute certainty. That approach provides reviewers with a transparent understanding of how quality decisions were reached under real manufacturing conditions.

What governance weakness becomes visible when a contamination control strategy exists but operational performance continues to deteriorate? 

A governance concern emerges when the contamination control strategy functions primarily as a reference document instead of an active management system. Procedures may remain current, risk assessments may exist, and periodic reviews may be completed, yet operational decisions gradually drift away from the assumptions supporting those documents. 


Inspectors often identify situations where staffing changes, production demands, equipment modifications, maintenance activities, or facility utilization evolved without corresponding reassessment of contamination control risks. The written strategy continues to describe one operating environment while routine practice reflects another. 


Evidence that carries greater weight includes documented review of operational changes, reassessment of contamination risks following process modifications, management evaluation of performance trends, and adjustments to contamination control measures based on observed experience. 


A contamination control strategy remains effective when it continuously reflects how sterile operations are actually performed rather than how they were originally designed.

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can join the session, access materials, and manage your learning.

3. Join the Live Training
At the scheduled time, click Join Session and you’ll be connected to the live Webex session with the instructor.

4. Watch Again Anytime
After the session, the playback becomes available on the same course page so you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

Everything related to your webinar: access, materials, playback, and certification — lives in one place.
Simple. Organized. Professional.
Go ahead and reserve your seat with confidence.

Built on 20+ years of global regulatory training experience across FDA, EMA, MHRA, and ICH frameworks.
Trusted by professionals across 80+ countries.

Testimonials

This is an upcoming session. Feedback below reflects experiences from similar programs delivered by our expert faculty.

“Session was easy to follow even for non-core team members. That helped.”
- Production Officer
“Good balance. Not too basic, not too deep. Worked well for mixed team.”
- Manager, Regulatory Affairs
“Team found it useful. Especially for aligning understanding across functions.”
- Director, Operations

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Featured Courses